ABPI comments on UK branded medicines pricing

25 September 2015

The Association of the British Pharmaceutical Industry (ABPI) has responded to discussion in the UK media on the price of medicines in the country.

Alison Clough, acting chief executive of the ABPI, said: “The UK already lags behind the rest of Europe in investing in medicines and the NHS in England currently spends just under 10p in every £1 on branded medicines, which represents just under 10% of the overall NHS budget. Moreover, recent growth figures for branded medicines in the UK have been going down, raising concerns that NHS patients in the UK are losing out when it comes to accessing the latest medicines.”

She added that the ABPI is responsible for negotiating with the government on behalf of the pharma industry to establish the pricing of medicines in the UK. Under the Pharmaceutical Price Regulation Scheme the pharma industry contributes and pays for the growth of branded medicines used in the National Health Service. In 2015 alone, ABPI members will pay back nearly £1 billion ($1.5 billion) in payments to the UK government.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK